Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and advanced metastatic MCC frequently responds to PD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Topalian, Suzanne L., Bhatia, Shailender, Amin, Asim, Kudchadkar, Ragini R., Sharfman, William H., Lebbé, Celeste, Delord, Jean-Pierre, Dunn, Lara A., Shinohara, Michi M., Kulikauskas, Rima, Chung, Christine H., Martens, Uwe M., Ferris, Robert L., Stein, Julie E., Engle, Elizabeth L., Devriese, Lot A., Lao, Christopher D., Gu, Junchen, Li, Bin, Chen, Tian, Barrows, Adam, Horvath, Andrea, Taube, Janis M., Nghiem, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
Rapid Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7392746/
https://ncbi.nlm.nih.gov/pubmed/32324435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00201
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados